Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| endothelial cell | 5 studies | 22% ± 6% | |
| epithelial cell | 4 studies | 24% ± 4% | |
| astrocyte | 4 studies | 22% ± 3% | |
| GABAergic neuron | 3 studies | 32% ± 10% | |
| glutamatergic neuron | 3 studies | 41% ± 14% | |
| abnormal cell | 3 studies | 24% ± 6% | |
| transit amplifying cell | 3 studies | 23% ± 10% | |
| oligodendrocyte | 3 studies | 23% ± 2% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| brain | 5 studies | 28% ± 10% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| esophagus | 100% | 7805.66 | 1445 / 1445 | 100% | 91.07 | 183 / 183 |
| ovary | 100% | 5767.77 | 180 / 180 | 100% | 90.50 | 430 / 430 |
| prostate | 100% | 8798.98 | 245 / 245 | 100% | 93.83 | 502 / 502 |
| uterus | 100% | 7150.79 | 170 / 170 | 100% | 97.85 | 459 / 459 |
| brain | 100% | 7033.56 | 2640 / 2642 | 100% | 80.97 | 705 / 705 |
| thymus | 100% | 7620.10 | 653 / 653 | 100% | 75.61 | 604 / 605 |
| lung | 100% | 8001.22 | 578 / 578 | 100% | 86.09 | 1153 / 1155 |
| breast | 100% | 5937.29 | 459 / 459 | 100% | 100.83 | 1116 / 1118 |
| skin | 100% | 7662.36 | 1809 / 1809 | 100% | 117.78 | 471 / 472 |
| stomach | 100% | 6105.27 | 359 / 359 | 100% | 80.91 | 285 / 286 |
| kidney | 100% | 8925.13 | 89 / 89 | 99% | 70.29 | 896 / 901 |
| intestine | 100% | 7911.94 | 966 / 966 | 99% | 79.98 | 524 / 527 |
| bladder | 100% | 7362.62 | 21 / 21 | 99% | 87.31 | 501 / 504 |
| pancreas | 99% | 3734.96 | 326 / 328 | 100% | 78.13 | 178 / 178 |
| liver | 100% | 5888.27 | 226 / 226 | 99% | 81.71 | 402 / 406 |
| adrenal gland | 100% | 9563.69 | 258 / 258 | 97% | 64.11 | 223 / 230 |
| adipose | 100% | 5711.51 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 100% | 67.80 | 80 / 80 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 87.75 | 29 / 29 |
| muscle | 100% | 8334.08 | 803 / 803 | 0% | 0 | 0 / 0 |
| spleen | 100% | 8004.16 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 80.33 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 34.18 | 1 / 1 |
| blood vessel | 100% | 6312.42 | 1334 / 1335 | 0% | 0 | 0 / 0 |
| heart | 99% | 7643.18 | 855 / 861 | 0% | 0 | 0 / 0 |
| peripheral blood | 98% | 7483.26 | 911 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0006406 | Biological process | mRNA export from nucleus |
| GO_0032210 | Biological process | regulation of telomere maintenance via telomerase |
| GO_0000184 | Biological process | nuclear-transcribed mRNA catabolic process, nonsense-mediated decay |
| GO_0035303 | Biological process | regulation of dephosphorylation |
| GO_0032204 | Biological process | regulation of telomere maintenance |
| GO_0005829 | Cellular component | cytosol |
| GO_0005697 | Cellular component | telomerase holoenzyme complex |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0005634 | Cellular component | nucleus |
| GO_0070034 | Molecular function | telomerase RNA binding |
| GO_0051721 | Molecular function | protein phosphatase 2A binding |
| GO_0042162 | Molecular function | telomeric DNA binding |
| GO_0031625 | Molecular function | ubiquitin protein ligase binding |
| GO_0005515 | Molecular function | protein binding |
| GO_0042826 | Molecular function | histone deacetylase binding |
| Gene name | SMG5 |
| Protein name | Nonsense-mediated mRNA decay factor SMG5 (EST1-like protein B) (LPTS-RP1) (LPTS-interacting protein) (SMG-5 homolog) (hSMG-5) |
| Synonyms | KIAA1089 EST1B |
| Description | FUNCTION: Plays a role in nonsense-mediated mRNA decay. Does not have RNase activity by itself. Promotes dephosphorylation of UPF1. Together with SMG7 is thought to provide a link to the mRNA degradation machinery involving exonucleolytic pathways, and to serve as an adapter for UPF1 to protein phosphatase 2A (PP2A), thereby triggering UPF1 dephosphorylation. Necessary for TERT activity. . |
| Accessions | Q9UPR3 ENST00000361813.5 |